" class="no-js "lang="en-US"> Yaniv Erlich - Medtech Alert
Thursday, February 26, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Yaniv Erlich

Yaniv Erlich

About Yaniv Erlich

  • Previously: Chief Science Officer of MyHeritage (acquired by Francisco Partners), Associate Professor of Computer Science at Columbia University (2015-2019). Principal Investigator at Whitehead Institute, MIT (2010-2015).
  • 50 peer-reviewed publications. Burroughs Wellcome Career Award, DARPA Young Faculty Award, Weintraub Award for PhD studies, IEEE-CS/ACM PhD award.
  • Raised $20M from a diverse portfolio including: DARPA, NIH, DoJ, Gates & CTTSO